NCT07298772

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Phase Ib/II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 198 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	SHR-4375 Injection	SHR-4375 injection.
DRUG	Bevacizumab Injection	Bevacizumab injection.
DRUG	Fluorouracil injection	Fluorouracil injection.
DRUG	Calcium Folinate Injection	Calcium Folinate injection.
DRUG	Paclitaxel for injection	Paclitaxel for injection.
DRUG	Oxaliplatin injection	Oxaliplatin injection.

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-01-01
• Completion: 2028-01-01
• First posted: 2025-12-23
• Last updated: 2025-12-23

Locations

1 site across 1 country: China